EUVIMEDEUVIMED entdecken
Crossref

Molecular and Clinical Risk Factors Associated with Thrombosis and Bleeding in Myelofibrosis Patients

Olga Morath, Carl Crodel, Jenny Rinke, Inken Sander, Aysun Tekbas, Manja Meggendorfer, Constance Baer, Andreas Hochhaus, Thomas Ernst

Hämostaseologie · 01.06.2026 · 46 (03) · 171-178

DOI: 10.1055/a-2410-8530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hämostaseologie, erschienen am 01.06.2026. Verfasst von Olga Morath und 8 weiteren Autor:innen. Beteiligte Einrichtung: Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Janus Kinase 2, Hemorrhage, Thrombosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The risk of thrombosis and bleeding in myelofibrosis (MF) has been historically underappreciated. We sought to investigate potential molecular and clinical risk factors for venous (VTE) and arterial (ATE) thrombotic events as well as bleeding episodes.

Methods

Data from 246 consecutive MF patients were analyzed. Driver mutations were tested in 191 patients.

Results

In total, 181 mutations were found in 177 MF patients: 118 (61.8%) patients showed JAK2-V617F, 50 patients (26.2%) showed CALR, and 6 patients (3.1%) showed MPL mutations. Two patients were JAK2-V617F and MPL positive and one patient was positive for all three genes. Fourteen (7.3%) patients were triple negative. The JAK2-V617F allele burden was assessed in 63 JAK2-V617F-mutated patients, revealing a median of 35.6% (range: 5.0–96.0). At the time of MF diagnosis and during follow-up, 84 thrombotic events (52 VTEs and 32 ATEs) were observed, corresponding to 6.6% of patients per year. A significant association was found between JAK2-V617F mutation (OR: 2.5, 95% CI: 1.1–5.6) and prior VTE (OR: 7.6, 95% CI: 2.1–27.1) with an increased risk of VTE. Patients with prefibrotic MF had a higher rate of ATE than patients with overt MF. Hemorrhagic events occurred in 34 (13.8%) patients, corresponding to 3.8% of patients per year. Fibrosis grade 3 was associated with bleeding risk (OR: 3.4, 95% CI: 1.2–9.2, p = 0.02).

Conclusions

The presence of the JAK2-V617F mutation, regardless of allele burden, and prior thrombosis were strongly associated with an increased risk of VTE. Patients with prefibrotic MF might be considered at high risk for developing ATE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisJanus Kinase 2HemorrhageThrombosisGenetic Predisposition to DiseaseHumansFemaleMaleRisk FactorsAgedMiddle AgedMutationReceptors, ThrombopoietinAged, 80 and overComorbidityAdultCalreticulinPrevalence

Substanzen

Janus Kinase 2JAK2 protein, humanReceptors, ThrombopoietinMPL protein, humanCalreticulinCALR protein, human

Autor:innen und Institutionen

  • Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.
  • Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Universitätsklinikum Jena, Jena, Germany.
  • MLL Münchner Leukämielabor GmbH, München, Germany.

Zitieren

APA

Morath, O., Crodel, C., Rinke, J., Sander, I., Tekbas, A., Meggendorfer, M., Baer, C., Hochhaus, A., & Ernst, T. (2026). Molecular and Clinical Risk Factors Associated with Thrombosis and Bleeding in Myelofibrosis Patients. Hämostaseologie, 46(03), 171-178. https://doi.org/10.1055/a-2410-8530

Vancouver

Morath O, Crodel C, Rinke J, Sander I, Tekbas A, Meggendorfer M, et al. Molecular and Clinical Risk Factors Associated with Thrombosis and Bleeding in Myelofibrosis Patients. Hämostaseologie. 2026;46(03):171-178. doi:10.1055/a-2410-8530

BibTeX
@article{Morath2026,
  author = {Morath, Olga and Crodel, Carl and Rinke, Jenny and Sander, Inken and Tekbas, Aysun and Meggendorfer, Manja and Baer, Constance and Hochhaus, Andreas and Ernst, Thomas},
  title = {Molecular and Clinical Risk Factors Associated with Thrombosis and Bleeding in Myelofibrosis Patients},
  journal = {Hämostaseologie},
  year = {2026},
  volume = {46},
  number = {03},
  pages = {171--178},
  doi = {10.1055/a-2410-8530}
}
Kostenlos starten →